New therapeutic strategies in liver fibrosis: Pathogenic basis

Medicina Clinica

Volumn 118, Issue 9, 2002, Pages 339-346

  Bataller, Ramón ^a   Ginès, Pere ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Chronic liver disease; Collagen; Cytokines; Hepatic fibrosis; Hepatic stellate cells

Indexed keywords

ALPHA INTERFERON; AMILORIDE; ANTIFIBRINOLYTIC AGENT; COLCHICINE; COLLAGEN; CORTICOSTEROID; GAMMA INTERFERON; HALOFUGINONE; INTERLEUKIN 10; LAMIVUDINE; LUFIRONIL; MALOTILATE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PLASMINOGEN ACTIVATOR INHIBITOR; RIBAVIRIN; S ADENOSYLMETHIONINE; SCATTER FACTOR; TOCOPHEROL;

ARTICLE; ASCITES; CELL PROLIFERATION; COLLAGEN DEGRADATION; CONGENITAL DISORDER; CONTROLLED STUDY; DISEASE COURSE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER HEMORRHAGE; LIVER TOXICITY; METABOLIC DISORDER; PATHOGENESIS; PROGNOSIS; VASCULAR DISEASE; LIVER CIRRHOSIS; REVIEW;

HUMANS; LIVER CIRRHOSIS;

EID: 0037117264     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)72380-4     Document Type: Article

References (67)

1. Liver fibrosis
2. Mechanisms and therapy of hepatic fibrosis: Report of the AASLD Single Topic Basic Research Conference
3. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis
4. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
5. Hepatic stellate cells as a target for the treatment of hepatic fibrosis
6. The role of liver biopsy in chronic hepatitis C
7. Natural history of liver fibrosis progression in patients with chronic hepatitis C
8. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study
9. Hepatic fibrosis: Are any of the serum markers useful?
10. Hepatitis C virus infection
11. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
12. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
13. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study
14. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
15. HCV-related fibrosis progression following liver transplantation: Increase in recent years
16. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
17. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
18. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver
19. New insights into hepatic stellate cell activation: The simple becomes complex
20. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
21. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells
22. Angiotensin II induces contraction and proliferation of human hepatic stellate cells
23. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human lto cells in culture
24. Fibrogenesis. V. TGF-beta signaling pathways
25. Molecular mechanism of the reversibility of hepatic fibrosis: With special reference to the role of matrix metalloproteinases
26. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis
27. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat
28. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy
29. Is liver fibrosis reversible?
30. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis
31. Current concepts in the pathogenesis of alcoholic liver injury
32. Acetaldehyde-induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: Studies with rat lipocytes and fibroblasts
33. Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells
34. Pathogenesis of liver fibrosis: Role of oxidative stress
35. Hepatic fibrogenesis and hepatitis C
36. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C
37. Activated human stellate cells express the cell machinery required for antigen presentation and modulate the proliferation of allogenic lymphocytes
38. Host genetic factors influence disease progression in chronic hepatitis C
39. Is liver fibrosis reversible?
40. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors
41. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
42. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage
43. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct
44. Reversibility of hepatic fibrosis in autoimmune hepatitis
45. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone
46. Colchicine in the treatment of cirrhosis of the liver
47. Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis
48. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis
49. The prognosis of patients with alcoholic liver disease. An international randomized, placebo-controlled trial on the effect of malotilate on survival
50. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
51. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial
52. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial
53. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression
54. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis
55. Inhibition of the NA (+)/H (+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: An in vitro and in vivo study
56. Mechanism of cardiac fibrosis by angiotensin. New insight revealed by genetic engineering
57. Angiotensin converting enzyme inhibition attenuates the progression of rat liver fibrosis
58. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis
59. Hepatocyte growth factor gene therapy of liver cirrhosis in rats
60. Effects of interferon therapy in «non responder» patients with chronic hepatitis C
61. Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor
62. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats
63. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy
64. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat
65. URSO-panacea or placebo?
66. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis
67. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis